Publish Date: February 2013
Author: Jeffrey Michael Smith, Richard F. Lowe, Judith Fullerton, Sheena M. Currie, Laura Harris, Erica Felker-Kantor
Despite compelling evidence for the effectiveness of magnesium sulfate for pre-eclampsia/eclampsia management, concerns have persisted about its safety and potential for toxicity, particularly among providers in low- and middle-income countries. An article in the journal BMC Pregnancy and Childbirth co-authored by MCHIP staff mitigates these concerns, establishing magnesium sulfate as the drug of choice in these cases and as part of comprehensive management of the disease. It presents the results of an integrative review of literature to document the known incidences of severe adverse reactions to magnesium sulphate, and specific outcomes of interest related to its use.
To read the open access article, click here.